Sarvada Pharma

Mounjaro is a dual receptor agonist that targets glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of use: Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus. It should be used under the supervision of a healthcare professional with regular monitoring of blood sugar and overall health.

Mounjaro (Tirzepatide) is an injectable prescription medicine used in adults with type 2 diabetes mellitus to improve blood sugar (glucose) when combined with diet and exercise. Its safety in people with a history of pancreatitis is unknown, and it is not for use in type 1 diabetes.

Mounjaro is administered once weekly and can be taken at a time of day that suits you, but it should be used on the same day each week to maintain consistent dosing. While approved for type 2 diabetes, tirzepatide has also shown significant weight loss effects, even in people without diabetes, and is sometimes used off-label for this purpose under medical supervision.

Mounjaro (Tirzepatide) Injection is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL strengths. It is a prescription medicine for adults with type 2 diabetes, used along with diet and exercise to improve blood sugar (glucose) control. Its safety has not been established in people with a history of pancreatitis, so it should be used with caution and under the supervision of a healthcare professional.

Mounjaro 2.5 mg (Tirzepatide) Injection is a solution for injection available in a pre-filled pen, with each 0.6 ml containing 2.5 mg of Tirzepatide. It works by activating two gut hormone receptors, GIP and GLP-1, to help manage blood sugar levels. This dual action stimulates insulin release when glucose is high, reduces glucagon production in the liver, slows stomach emptying to control post-meal sugar spikes, and increases feelings of fullness to reduce appetite and food intake. Mounjaro is prescribed for adults with type 2 diabetes to improve glycemic control and support weight management, under the guidance of a healthcare professional.

Mounjaro 12.5 mg is primarily used for type 2 diabetes to help control blood sugar levels. It works by activating GIP and GLP-1 receptors, which stimulate insulin release when glucose is high, reduce glucose production by the liver, slow gastric emptying, and increase feelings of fullness.

Weight Loss: Although not officially approved for weight loss, Mounjaro 12.5 mg has shown significant weight reduction in clinical trials and may sometimes be prescribed off-label for this purpose under medical supervision.